TB006 Expanded Access (EA) Compassionate Use

Summary

This is an open-label, expanded access, compassionate use treatment protocol of TB006 treatment in participants who meet clinical diagnostic criteria for Alzheimer's disease (AD). Participants will receive TB006 at a dose of 4,000 milligrams (mg) intravenous (IV) over 1 hour every 28 days ± 5 days.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications